Landmark Bio

?? POSTmark features mirrored R&D and cGMP equipment, along with processes that are designed to seamlessly support all stages of development, from early-stage R&D through to commercial cGMP manufacturing. ? Our platform enables: ?? Rapid Transition: Move from R&D to cGMP scale in record time (6-9 months for cGMP AAV). ?? Streamlined Development: Research-grade AAV that mirrors cGMP AAV, ensuring consistency at every stage. ?? Cost and Risk Reduction: Minimize time, costs, and risks with an optimized process that accelerates your journey to market. Whether you're working on viral vector production or gene therapy, POSTmark offers a proven, scalable solution to bring your innovations to life faster and more efficiently. Read more about our Drug Development Services for Viral Vectors, including AAV here: ? #Biotech #CellAndGeneTherapy #cGMP #Innovation #BiotechManufacturing #ScaleUp #Biopharma #LifeSciences #BiotechInnovation

We're thrilled to announce that ChromaTan, Inc Inc. and Landmark Bio have been awarded a grant from the NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). This funding will support the development of an intensified recombinant adeno-associated virus (rAAV) production process, advancing gene therapy manufacturing. This collaboration leverages Landmark Bio’s expertise in viral vector process development, chemistry, manufacturing and controls (CMC), and GMP manufacturing. ? Click here to read the full press release: https://lnkd.in/gpNPFEYv We look forward to working with ChromaTan and contributing to the NIIMBL mission and community! #GeneTherapy #Manufacturing #NIIMBL #LandmarkBio #Innovation #Biopharmaceuticals

?? At Landmark Bio, our Platform Optimized for Scale-up and Transfer (POSTmark) is a game-changer for the biotech industry. Our platform enables: ?? Rapid Transition: Move from R&D to cGMP scale in record time (6-9 months for cGMP LVV). ?? Streamlined Development: Research-grade LVV that mirrors cGMP LVV, ensuring consistency at every stage. ?? Cost and Risk Reduction: Minimize time, costs, and risks with an optimized process that accelerates your journey to market. ? Whether you're working on viral vector production or gene therapy, POSTmark offers a proven, scalable solution to bring your innovations to life faster and more efficiently. ? Read more about our Drug Development Services for Viral Vectors, including LVV here: https://lnkd.in/eUQ84dfg ? #Biotech #CellAndGeneTherapy #cGMP #Innovation #R&D #BiotechManufacturing #ScaleUp #Biopharma #LifeSciences #BiotechInnovation

Today, we celebrate the incredible women who have shaped our past, are leading in the present, and will continue to inspire the future. From leaders in business, science, technology, and the arts to the everyday women who make a difference, this day serves as a reminder of how far we've come—and how much further we can go together! Let's commit to lifting the voices of women around the world, creating more inclusive workplaces, and fostering an environment where all women can thrive! #InternationalWomensDay #IWD2025 #WomenInLeadership #Empowerment #WomenInSTEAM #AccelerateAction

?? Today, let's raise our voices and spread awareness for those living with rare diseases. By sharing stories, supporting research, and advocating for better access to care and treatment, we can create a world that values every patient, no matter how rare their condition may be. Let’s continue pushing for innovations in medical care, research funding, and policy changes that will make a lasting impact! To learn more about how you can get involved, please visit: https://lnkd.in/gk6hbAF #RareDiseaseDay #PatientAdvocacy #TogetherWeCan

Landmark Bio’s Associate Vice President & Quality Site Head, Mike Sousa, Associate Vice President of Process & Analytical Development, Eli Kraus, and Senior Director of Analytical Sciences, Manish Tandon, recently published an article entitled, Integrating Analytical Method Development and Quality Control: A Roadmap for Successful Advanced Therapy Development. Aligning and integrating Analytical Method Development (AMD) and Quality Control (QC) activities is crucial to the drug product life cycle. This collaboration ensures a smooth method transfer and brings numerous benefits that can drive the successful development and commercialization of the drug product. To read further, please follow the link: https://lnkd.in/ezBdEnHJ #AnalyticalMethodDevelopment #QualityControl #CellandGeneTherapies

Are you ready to take your advanced therapy from research to market? At Landmark Bio, we recognize that the definition of process and product is closely linked for advanced therapies. A deep understanding of your product is crucial to developing robust manufacturing processes. We invite you to join our upcoming webinar, where Michael Covington and Gregg Nyberg will cover essential topics, such as translating protocols into strong manufacturing processes using Quality by Design principles, scaling your manufacturing to meet projected market demand, and demonstrating comparability to ensure your product is commercially ready. Discover how we can help you navigate these complexities and achieve your commercial goals. Don’t miss out - register today to secure your spot: https://lnkd.in/gHVHchWh #QualitybyDesign #AdvancedTherapies #Manufacturing #Commercialization #Biotech

In celebration of the Super Bowl, we hosted our third annual “Dip Off” contest, where team members brought their favorite game day dips to share! It was a blast sampling all the delicious creations and bonding as a team. ? We’re also thrilled to be recognized by Built In as one of the 50 Best Startups to Work For and one of the 100 Best Places to Work in Boston for 2025! We are feeling extremely grateful for this amazing team. ? #EmployeeEngagement #CompanyCulture #2025BuiltInBest

Did you know that a significant portion of delays in clinical development stems from Chemistry, Manufacturing, and Controls (CMC) issues? At Landmark Bio, we believe in the power of proactive planning. That's why we stress the importance of establishing your regulatory and CMC strategies early in development. We invite you to join our upcoming webinar, partnered with Outsourced Pharma, where Landmark's Michael Covington and Gregg Nyberg will explore how to effectively define your product, identify potential gaps and risks in your CMC program, and discuss strategies for engaging with health authorities to mitigate risks and pave a smoother path to commercialization. Learn from our experts as they guide you in crafting a robust CMC roadmap that can support your development timelines and save you time and resources. Don’t miss this opportunity to gain insights that can transform your approach - register now: https://lnkd.in/gHVHchWh #CMCStrategy #RegulatoryAffairs #DrugDevelopment #CellAndGeneTherapy

In the article Landmark Bio’s Mission to Prevent Cell Therapy ‘Do-Overs’, featured in Drug, Discovery & Development, Landmark Bio is revolutionizing cell and gene therapy with a strategic approach focused on early planning and long-term impact. Our CEO, Ran Zheng, highlights the importance of designing with the future in mind to ensure efficient scaling and avoid costly re-engineering. Click on the article to learn how Landmark Bio prioritizes patient outcomes and ecosystem growth, driving innovation in this transformative field. https://lnkd.in/eVFgCKRY #Biotech #CellAndGeneTherapy #HealthcareInnovation #PublicBenefit